RAPH · Raphael Pharmaceutical Inc.
$1.40
At close · Jul 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.25M
Shares
20.18M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$1.28M
+15.8%
FY2025
Diluted EPS
$0.07
-12.5%
FY2025
Operating Cash Flow
-$210K
+60.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $495K | $631K | $776K | $569K | $1.18M | $776K | $461K | |
| $432K | $614K | $733K | $763K | $2.14M | $853K | $245K | |
| -$927K | -$1.25M | -$1.51M | -$1.33M | -$3.32M | -$1.63M | -$706K | |
| -$53K | -$34K | -$10K | -$12K | -$41K | $4000 | -$12K | |
| -$980K | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.63M | -$718K | |
| — | — | — | -$1.28M | -$3.36M | -$1.63M | -$718K | |
| — | — | — | — | $3.36M | $1.63M | -$718K | |
| USD/shares | $0.05 | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | — |
| USD/shares | $0.05 | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | — |
| shares | — | 19.55M | 18.67M | 16.72M | 14.34M | 11.17M | 9.46M |
| shares | — | 19.55M | 18.67M | 16.72M | 14.34M | 11.17M | 9.46M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 0.94×
EV/EBIT
—
Peer median 8.91×
P/E (TTM)
—
Peer medians compare against the 37 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).